Related Topics


Companies


  

Category: avastin

Latest news
September 02. 2010
The ASCO post publishes multiple perspectives on outcome of ODAC meeting regarding Bevacizumab in advanced breast cancer
August 25. 2010
UK's NICE again rejects Roche's advanced bowel cancer drug Avastin
August 20. 2010
Avastin mugging - FDA rigs the verdict against a good cancer drug
August 16. 2010
FDA considers revoking approval of Avastin for advanced breast cancer
August 06. 2010
Avastin shows longest overall survival for patients with adenocarcinoma, the most common type of advanced lung cancer
August 02. 2010
Senator slams FDA advisory committee's Avastin decision
July 22. 2010
Large ‘real-world’ study shows Avastin-based therapy extends survival beyond fourteen months in patients with advanced lung cancer
July 21. 2010
Genentech provides update from Avastin FDA Advisory Committee meeting
July 20. 2010
New study backs Roche's Avastin in lung cancer
July 12. 2010
Roche's Avastin rejected by UK's NICE in draft guidance due to "uncertain evidence base"
July 02. 2010
Second phase III study showed Avastin-containing regimen helped women with ovarian cancer live longer without their disease getting worse
June 11. 2010
Kidney damage affirmed with biologic-chemo combo
June 11. 2010
Study backs Roche's Avastin as cheap eye treatment
June 07. 2010
Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening
June 03. 2010
Roche provides update on Phase III study with Avastin in aggressive non-Hodgkin’s Lymphoma
April 20. 2010
Celtic Pharma announces preclinical findings that XERECEPT potentiates significantly the tumor inhibition activity of Avastin
March 12. 2010
Genentech provides update on phase III study of Avastin in men with late stage prostate cancer
February 25. 2010
Avastin phase III study shows positive results in women with advanced ovarian cancer
February 23. 2010
Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint
January 22. 2010
New real world Avastin data from over 3,200 metastatic colorectal cancer patients confirms survival benefit beyond 2 years
January 06. 2010
OncoMethylome Sciences to perform MGMT testing in Roche Phase III study of Avastin for glioblastoma
December 18. 2009
Surveyed European oncologists cite cost most frequently as the factor preventing their use of Avastin for non-small-cell lung cancer
December 16. 2009
For breast cancer treatment, an agent that can achieve an overall survival benefit would pose the greatest challenge to Avastin's dominance in europe
December 14. 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
December 09. 2009
Important progress in treatment of early and late stage breast cancer with Herceptin, Avastin and T-DM1
November 26. 2009
UK cost body again rejects Roche bowel cancer drug
November 23. 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
November 18. 2009
World's first delivery of intra-arterial Avastin directly into brain tumor
November 17. 2009
Genentech submits supplemental applications to FDA for Avastin combined with commonly used chemotherapies for women with advanced breast cancer
October 29. 2009
Medicare reverses billing change on Genentech drug
September 25. 2009
New data presented at ECCO/ESMO confirms benefits of bevacizumab (Avastin) based therapy for the first-line treatment of metastatic breast cancer
September 24. 2009
From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases
September 23. 2009
Roche announces results from two early studies which show promise for patients with malignant melanoma
September 23. 2009
Roche: Phase IV lung cancer study confirms the safety and outstanding efficacy benefit of Avastin-based therapy in a ‘real world’ setting
September 22. 2009
Roche: Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer
September 21. 2009
Roche to present new survival data from phase II, III and IV studies for Avastin, Herceptin and Xeloda
August 24. 2009
Genentech: First phase III study to indicate PFS benefit of Avastin PlusChemotherapy as 2nd line treatment for advanced breast cancer
August 18. 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
August 03. 2009
FDA approves Avastin for the most common type of kidney cancer
July 29. 2009
European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced breast cancer
July 09. 2009
Roche's Avastin drug shrinks ear-nerve tumors
July 03. 2009
Roche Pharma Switzerland receives the sixth Walter Siegenthaler Medien und Medizin Verlag (MMV) Award for Avastin
June 02. 2009
Roche reports maintenance treatment with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worsening
June 02. 2009
Genentech reports Avastin plus commonly used chemotherapies improved progression-free survival in advanced breast cancer
June 02. 2009
Roche announces full results from first Phase III study of Avastin in adjuvant colon cancer
May 06. 2009
FDA grants accelerated approval of Avastin for brain cancer that has progressed following prior therapy
April 23. 2009
Surveyed experts indicate that the combination of Sutent and Taxol has advantages over the combination of Avastin and Taxol in the treatment of metastatic triple-negative breast cancer
April 23. 2009
Genentech buyout price looking better on Avastin adjuvant miss
April 22. 2009
Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint
April 01. 2009
Avastin label updated reflecting confidence in safety profile